Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Jaguars cut WR Zay Jones, clearing a path to potentially sign five
Williamson to lead New Zealand at the Twenty20 World Cup; Southee to make his 7th appearance
Williamson to lead New Zealand at the Twenty20 World Cup; Southee to make his 7th appearance
United Methodists prepare for votes on lifting LGBTQ bans and other issues at General Conference
Walmart shutting down its 51 health care clinics, virtual care service
'Flying Apsaras' takes flight in Beijing, set for nationwide tour
Who is Humza Yousaf's wife Nadia El
Egyptian, Chinese students mark UN Chinese Language Day in Cairo
5 takeaways from the global negotiations on a treaty to end plastic pollution
South African boxer Dingaan Thobela, 'The Rose of Soweto,' dies aged 57
Entire mall in Georgia is closed after 'shots are fired inside